RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 44 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 44

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of North Sichuan Medical College川北医学院附属医院NanchongHospital page
  2. Study siteAffiliated Hospital of Qinghai University青海大学附属医院XiningHospital page
  3. Study siteAffiliated Hospital of Southwest Medical University西南医科大学附属医院LuzhouHospital page
  4. Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
  5. Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
  6. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  7. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  8. Study siteFirst Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第一医院HarbinHospital page
  9. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  10. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  11. Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
  12. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  13. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  14. Study siteFirst Hospital of Lanzhou University兰州大学第一医院LanzhouHospital page
  15. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  16. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  17. Study siteGuizhou Provincial People's Hospital贵州省人民医院GuiyangHospital page
  18. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  19. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  20. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  21. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  22. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
  23. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  24. Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
  25. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  26. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  27. Study siteNingbo Medical Center Lihuili Hospital宁波市医疗中心李惠利医院NingboHospital page
  28. Study sitePeking University Shenzhen Hospital北京大学深圳医院ShenzhenHospital page
  29. Study siteSecond Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University温州医科大学附属第二医院WenzhouHospital page
  30. Study siteSecond Affiliated Hospital of Anhui Medical University安徽医科大学第二附属医院HefeiHospital page
  31. Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
  32. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  33. Study siteShandong Provincial Hospital山东省立医院JinanHospital page
  34. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  35. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  36. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  37. Study siteTangshan People's HospitalTangshanHospital page
  38. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  39. Study siteWeifang People's Hospital潍坊市人民医院WeifangHospital page
  40. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  41. Study siteXiangyang Central Hospital襄阳市中心医院XiangyangHospital page
  42. Study siteXijing Hospital空军军医大学西京医院Xi'anHospital page
  43. Study siteXuzhou Central Hospital徐州市中心医院XuzhouHospital page
  44. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07047365, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Cytologically or histologically confirmed Human Epidermal Growth Factor Receptor 2 (HER2)-positive recurrent or metastatic breast cancer;

    Inclusion criterion 3

  3. ≥Grade 2 myocardial ischemia/infarction, arrhythmias, or congestive heart failure (New York Heart Association (NYHA)Class ≥II);

    Exclusion criterion 9

  4. Received ≥2 prior lines of anti-HER2 targeted therapy in the advanced setting;

    Inclusion criterion 4

    Chemotherapy, radiotherapy, or immunotherapy within 4 weeks before randomization (or within 5 half-lives of prior drugs, whichever is shorter);

    Exclusion criterion 19

    Prior HER2-targeted therapy-induced Left Ventricular Ejection Fraction (LVEF) decline to <50% or absolute reduction >15%;

    Exclusion criterion 23

  5. Age: 18-75 years (at time of signing Informed Consent Form (ICF); Eastern Cooperative Oncology Group (ECOG) performance status ≤1; estimated life expectancy >3 months;

    Inclusion criterion 2

  6. At least one measurable lesion meeting Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) criteria (excluding brain lesions);

    Inclusion criterion 5

  7. Other malignancies within 5 years before randomization or concurrent malignancies (except adequately treated non-melanoma skin cancer, in situ cervical cancer, or other cancers with curative treatment and no recurrence for ≥3 years);

    Exclusion criterion 2

    Immunodeficiency disorders (e.g., Human Immunodeficiency Virus (HIV) ;

    Exclusion criterion 14

  8. Female subjects of childbearing potential must agree to use effective contraception (e.g., Intrauterine Device (IUD), oral contraceptives, or condoms) during the study and for 6 months after study completion.

    Inclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07047365, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Subjects voluntarily participate in this study and sign the informed consent form;
  • Age: 18-75 years (at time of signing Informed Consent Form (ICF); Eastern Cooperative Oncology Group (ECOG) performance status ≤1; estimated life expectancy >3 months;
  • Cytologically or histologically confirmed Human Epidermal Growth Factor Receptor 2 (HER2)-positive recurrent or metastatic breast cancer;
  • Received ≥2 prior lines of anti-HER2 targeted therapy in the advanced setting;
  • At least one measurable lesion meeting Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) criteria (excluding brain lesions);
  • Willing to receive one of the investigator-selected chemotherapy regimens;
  • Adequate organ function;
  • Female subjects of childbearing potential must agree to use effective contraception (e.g., Intrauterine Device (IUD), oral contraceptives, or condoms) during the study and for 6 months after study completion.

Exclusion Criteria:

  • Concurrent Diseases and Medical History:
  • Other malignancies within 5 years before randomization or concurrent malignancies (except adequately treated non-melanoma skin cancer, in situ cervical cancer, or other cancers with curative treatment and no recurrence for ≥3 years);
  • Uncontrolled toxicities (>CTCAE Grade 1) from prior therapies (excluding alopecia);
  • Major surgery, open biopsy, or significant traumatic injury within 28 days before randomization;
  • Non-healing wounds or fractures;
  • Arterial/venous thromboembolic events within 6 months before randomization;
  • History of drug abuse or psychiatric disorders that may affect compliance;
  • Poorly controlled hypertension (e.g., Systolic Blood Pressure (SBP) >160 mmHg despite treatment);
  • ≥Grade 2 myocardial ischemia/infarction, arrhythmias, or congestive heart failure (New York Heart Association (NYHA)Class ≥II);
  • Active or uncontrolled severe infections (≥CTCAE Grade 2);
  • Known chronic hepatitis B;
  • Active syphilis infection;
  • Renal failure requiring hemodialysis/peritoneal dialysis;
  • Immunodeficiency disorders (e.g., Human Immunodeficiency Virus (HIV) ;
  • Poorly controlled diabetes;
  • Urine protein ≥++ on dipstick with 24-hour urine protein >1.0 g;
  • Epilepsy requiring medication.
  • Tumor-Related Conditions and Treatments:
  • Chemotherapy, radiotherapy, or immunotherapy within 4 weeks before randomization (or within 5 half-lives of prior drugs, whichever is shorter);
  • Chinese herbal medicines with approved antitumor indications (per National Medical Products Administration (NMPA) labeling) within 2 weeks;
  • Severe Bone Lesions from bone metastases;
  • Untreated brain metastases, Leptomeningeal metastases, or carcinomatous meningitis;
  • Prior HER2-targeted therapy-induced Left Ventricular Ejection Fraction (LVEF) decline to <50% or absolute reduction >15%;
  • Uncontrolled or symptomatic Hypertension requiring ongoing bisphosphonates;
  • Uncontrolled cancer-related pain;
  • Existed Lymphangitis Carcinomatosa or uncontrolled effusions;
  • Use of Immunosuppressant or systemic corticosteroids (≥10 mg/day prednisone equivalent) within 2 weeks.
  • Severe hypersensitivity to monoclonal antibodies;
  • Participation in other antitumor clinical trials with investigational drugs within 4 weeks before randomization;
  • Any condition deemed by the investigator to jeopardize subject safety or study completion.

Quoted from ClinicalTrials.gov, NCT07047365, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07047365, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07047365